



MEDIZINISCHE  
FAKULTÄT

# Standardized psychological investigation of 59 patients with congenital hyperinsulinism

**A. Ludwig, K. Ziegenhorn, S. Empting, T. Meissner\*, J. Marquard\*, K. Mohnike**

**University paediatric hospitals Magdeburg and \*Düsseldorf**

# Literature overview

Author /Journal	Patients (n)	Neurological outcome
Izumi et al (Japan) Acta Paediatr Jap 1997; 39: 10-17	5 (5/5 pancreatectomy)	4/5 epilepsy (4-22y.)
Cresto et al Arch dis Child 1998; 79(5): 440-4	26 (10/26 pancreatic resection)	11/26 neurological sequelae
Mahachoklertwattana et al (Thailand) J Pediatr Endocrinol Metab 2000; 13(1): 37-44	7/10 (neonate; Group 1 infantile; Group 2)	6/7 delayed development and subnormal IQ
Rother et al (USA) Ped. Diabetes 2001; 2(3): 115-22	8/15 (15/15 subtotal pancreatectomy 5/15 initially seizures 2/15 mental retardation)	8/8 attentional control impairment 4/8 subnormal intellectual functioning

## Literature overview

Author /Journal	Patients (n)	Neurological outcome																																			
Menni et al (France) Pediatrics 2001; 107: 476-479.	90 (63 treated surgically 27 treated medically) Subsequent Normal Development; Group 1) Intermediate Disability; (Group 2) Severe Psychomotor Retardation; (Group 3)	<table border="1"> <thead> <tr> <th></th> <th>n</th> <th>Gr1</th> <th>Gr2</th> <th>Gr3</th> </tr> </thead> <tbody> <tr> <td>All patients</td> <td>90</td> <td>74%</td> <td>18%</td> <td>8%</td> </tr> <tr> <td>Neonates</td> <td>54</td> <td>68%</td> <td>21%</td> <td>11%</td> </tr> <tr> <td>Infants</td> <td>36</td> <td>82%</td> <td>15%</td> <td>3%</td> </tr> <tr> <td>Diffuse form</td> <td>34</td> <td>75%</td> <td>14%</td> <td>9%</td> </tr> <tr> <td>Focal form</td> <td>29</td> <td>68%</td> <td>22%</td> <td>10%</td> </tr> <tr> <td>Medical treatment</td> <td>27</td> <td>80%</td> <td>16%</td> <td>4%</td> </tr> </tbody> </table>		n	Gr1	Gr2	Gr3	All patients	90	74%	18%	8%	Neonates	54	68%	21%	11%	Infants	36	82%	15%	3%	Diffuse form	34	75%	14%	9%	Focal form	29	68%	22%	10%	Medical treatment	27	80%	16%	4%
	n	Gr1	Gr2	Gr3																																	
All patients	90	74%	18%	8%																																	
Neonates	54	68%	21%	11%																																	
Infants	36	82%	15%	3%																																	
Diffuse form	34	75%	14%	9%																																	
Focal form	29	68%	22%	10%																																	
Medical treatment	27	80%	16%	4%																																	
Jack et al (Australia) Clin Endocrinol 2003; 58(3): 355-64	62 Group A: euglycemic < 35 days Group B: non-euglycemic > 35 days  Neurological outcome (normal, mild deficit, severe deficit)	no different between Group A / B 44% with neurological deficits Group A: medical treatment 7/ 15 (4 mild; 3 severe deficit) Surgical treatment 2/ 18 (2 mild; 0 severe deficit)																																			
Meissner et al (Germany) Eur J Endocrinol 2003; 149: 43-51	114 using standard questionnaire	44% high degree of psychomotor or mental retardation 25% epilepsy																																			

# Literature overview

Author /Journal	Patients (n)	Neurological outcome
Cherian et al Saudi Arabia J Pediatr Endocrinol Metab 2005; 18(12): 1441-8	10 (10/10 pancreatectomy 95 %)	1/10 sustained subarachnoid hemorrhage, cerebral edema, seizures in neonatal period 9/10 neurologically and developmentally normal
Mazor-Aronovitch et al (Israel) Eur J Endocrinol 2007; 157(4): 491-7	21 Ashkenazi CH medically treated (10/21 perinatal seizures of short duration 4/21 post-neonatal seizures, which remitted entirely) Telephone interview using standard questionnaire	<i>Early childhood:</i> 4/21 hypotonia 8/21 fine motor problems 7/21 gross motor problems (clumsiness) 1/21 mild cerebral palsy 3/21 speech problems 8/21 required developmental therapy <i>School age:</i> 21/21 regular education 6/21 learning problems
Mercimek-Mahmutogly et al (Austria) J Pediatr Endocrinol Metab 2008; 21(6): 523-32	14 (7/14 pancreatectomy)	31% mental retardation 15% epilepsy

- Up to now only retrospective analysis (by reviewing hospital records or telephone interviews) of psychomotor development has been published
- motor and/ or intellectual disability in 138/257 children
- one prospective study in eight children (mean age  $12.7 \pm 0.8$ )
- Drawback of retrospective studies:
  - very selective cohorts, e.g. after (95%) pancreatectomy
  - Inhomogeneity for etiology, e.g. syndromic or unknown cause
  - no standardized psychometry
  - missing values, e.g. duration of hypoglycemia

**Prospective, standardized psychometric studies needed**

## INCLUSION CRITERIA

- ✓ clinical diagnosis of CHI
- ✓ mutation in KATP–channel genes
- ✓ metabolopathies: GCK, GLUD, others
- ✓ syndromic, chromosomal aberration
- ✓ no age limit

## CLINICAL DIAGNOSIS OF CHI

- ✓ glucose demand  $> 8 \text{ mg/kg/min}$
- ✓ glucagon response (30mg/kg s.c. or i.m.)
- ✓ simultaneous:
  - ✓ Glucose  $< 2.6 \text{ mmol/l}$
  - ✓ Insulin  $> 3 \text{ mU/l}$
- ✓ FFA  $< 600 \text{ mmol/l}$ , ketones (BOHB)  $< 0.1 \text{ mmol/l}$

# OBJECTIVES

## Primary objectives:

- intellectual and physical development and motor function of patients with congenital hyperinsulinism

## Secondary objectives:

- noticeable behaviour problems
- disturbance in quality of life (descriptive analysis)
- influence of hypoglycaemia based on nutrition




# Parental Home Magdeburg



## PATIENTS and METHODS

- 59 patients ( male=35; age: 3 months up to 57 years)
- Genetic defects: ABCC8 (n=16), KCNJ11 (n=4), Glucokinase (n=3), GDH (n=2)
- Application of **standardized psychological procedures** to acquire data of cognitive, speech and social-emotional development in patients with hyperinsulinism


# Standardized psychometric tests



## RESULTS

	<b>0-3 years</b>	<b>3-6 years</b>	<b>6-17 years</b>	<b>adults</b>
cognitive impairment	7%	21%	9%	42%
speech delay	22%	-	-	-
motor delay	35%	20%	42%	-
social-emotional delay/ behaviour	4%	no	36%	no

# Cognitive Development (M=100; SD=15)



## CONCLUSION

- 26 of 59 patients show developmental delay
- A connection with the basis defect could not be detected (up to now)
- Motor delays dominate (one out of three)
- An early integration of patients in therapeutic treatments (e. g. occupational therapy) is essential to prevent further delay